Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Abbott Laboratories    ABT

Delayed Quote. Delayed  - 09/26 10:04:30 pm
41.68 USD   -1.21%
09/21 ABBOTT LABORATO : Malnutrition Adds $15.5 Billion Annually to Direct..
09/21DJABBOTT LABORATO : to Delist from London Stock Exchange
09/21 ABBOTT : Hosts Conference Call for Third-Quarter Earnings
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

European Medical Group Changes Drug Data-Release Policy After Criticism

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/22/2012 | 06:28pm CEST
   By Peter Loftus 
   Of  
 

A European medical society has changed its plans for releasing results of clinical studies of liver-disease therapies after some critics said the original plan would have amounted to selective disclosure to certain investors.

The studies are expected to include potentially market-moving results of trials involving hepatitis C drugs in development at Abbott Laboratories (>> Abbott Laboratories), Bristol-Myers Squibb Co. (>> Bristol Myers Squibb Co.) and Gilead Sciences Inc. (GILD).

The European Association for the Study of the Liver now plans to publicly release summaries of most of the studies online April 4, two weeks ahead of the association's International Liver Congress meeting in Barcelona.

Under the new policy, certain studies selected to be highlighted by EASL's press office won't be made available publicly until the date and time of their presentation at the conference, which runs April 18-22. EASL didn't say which studies will be selected. However, EASL said they won't be made available in advance to non-media conference participants before the embargoes lift.

Previously, EASL had planned to make the summaries available online Thursday, but only accessible to EASL members and those registered for the conference, which includes analysts and investors. EASL also previously planned to prohibit media registered to attend the conference from reporting on the summaries until the conference.

Critics of the policy, including TheStreet.com reporter Adam Feuerstein, said the original plans amounted to selective disclosure by providing material information to people who paid to attend the conference, while unfairly leaving others in the dark.

"EASL is making these changes in light of recent criticism of its proposed policy, which suggests that 'selective distribution' of officially accepted clinical data in advance of the Congress would make our proposed embargo policy untenable," EASL said in a written statement Thursday.

The presentation of drug data at medical meetings has long posed a conundrum for companies and investors. Some conferences have made changes in their policies to address concerns.

The American Society of Clinical Oncology, for instance, used to distribute study summaries to participants at its annual meeting weeks ahead of the conference, but prohibit media from reporting the contents until the conference.

ASCO has since changed its policy so that now most summaries are posted publicly online a few weeks before the annual scientific meeting, while certain featured studies aren't publicly disclosed until the meeting.

Scott Gottlieb, a physician and resident fellow at the American Enterprise Institute who has criticized certain medical meeting embargo policies, said EASL did the right thing.

"I think the days of conferences engaging in selective release of important study results are probably over," he said. "ASCO yielded to this truth, EASL did, and I suspect other major conferences will be that much more reluctant to now buck these precedents."

-By Peter Loftus, Dow Jones Newswires; +1-215-982-5581; peter.loftus@dowjones.com

Stocks mentioned in the article : Abbott Laboratories, Bristol Myers Squibb Co.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ABBOTT LABORATORIES
09/21 ABBOTT LABORATORIES : Malnutrition Adds $15.5 Billion Annually to Direct U.S. Me..
09/21 DGAP-NEWS : Abbott Laboratories: Announcement of Intention to Delist
09/21DJABBOTT LABORATORIES : to Delist from London Stock Exchange
09/21 ABBOTT : Hosts Conference Call for Third-Quarter Earnings
09/21 ABBOTT LABORATORIES : MILITARY $38,669 Federal Contract Awarded to Abbott Labora..
09/20 ABBOTT LABORATORIES : Justification and Approval - Abbott Laboratories Chemical ..
09/20 FUELING PERFORMANCE WITH FAT : EAS® Launches First Ketogenic Meal Replacement Fo..
09/19 ABBOTT LABORATORIES : Nippon Life Insurance Co Lowers stake in Abbott Laboratori..
09/17 JOHNSON & JOHNSON : to buy Abbott's vision unit for $4.3B
09/17DJJ&J to Buy Abbott Eye Business -- WSJ
More news
Sector news : Pharmaceuticals - NEC
08:49aDJPFIZER : Scraps Plan to Break Up Company -- WSJ
09/26DJMYLAN : EpiPen Pretax Profits 60% Higher Than Number Told to Congress -- 3rd Upd..
09/26 MYLAN : faces scrutiny over EpiPen profit data shown to Congress
09/26DJPFIZER : Throws Out Plan to Split Into Two Companies -- 2nd Update
09/26DJPfizer Throws Out Plan to Split Into Two Companies
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
09/26 Amazon's Next Step Toward Global Domination
09/22 JOHNSON & JOHNSON : From Dead Money To Amongst The Best In My Portfolio
09/21 Presenting Apple's First Car
09/20 A Unique Method To Value Dividend Stocks Based On Expected Growth
09/20 My Top Picks For Q4
Advertisement
Financials ($)
Sales 2016 20 939 M
EBIT 2016 3 925 M
Net income 2016 2 235 M
Debt 2016 2 699 M
Yield 2016 2,49%
P/E ratio 2016 23,33
P/E ratio 2017 18,03
EV / Sales 2016 3,05x
EV / Sales 2017 2,92x
Capitalization 61 269 M
More Financials
Chart ABBOTT LABORATORIES
Duration : Period :
Abbott Laboratories Technical Analysis Chart | ABT | US0028241000 | 4-Traders
Full-screen chart
Technical analysis trends ABBOTT LABORATORIES
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Average target price 47,8 $
Spread / Average Target 15%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Miles D. White Chairman & Chief Executive Officer
Brian B. Yoor Chief Financial Officer & Senior VP-Finance
Roxanne Schuh Austin Independent Director
Jim Farrell Independent Director
Samuel C. Scott Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ABBOTT LABORATORIES-7.19%61 269
JOHNSON & JOHNSON14.66%322 232
ROCHE HOLDING LTD.-11.18%215 081
NOVARTIS AG-8.70%211 231
PFIZER INC.4.21%204 049
MERCK & CO., INC.17.66%171 858
More Results